{"created":"2023-05-15T14:37:31.980901+00:00","id":48414,"links":{},"metadata":{"_buckets":{"deposit":"4a41b125-c231-488d-a1cc-a1a246140d07"},"_deposit":{"created_by":1,"id":"48414","owners":[1],"pid":{"revision_id":0,"type":"depid","value":"48414"},"status":"published"},"_oai":{"id":"oai:repo.qst.go.jp:00048414","sets":["1"]},"author_link":["486674","486670","486671","486667","486673","486675","486664","486669","486662","486663","486668","486672","486666","486665"],"item_8_biblio_info_7":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2017-09","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"54","bibliographicPageEnd":"88826","bibliographicPageStart":"88815","bibliographicVolumeNumber":"8","bibliographic_titles":[{"bibliographic_title":"Oncotarget"}]}]},"item_8_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Bevacizumab, an anti-vascular endothelial growth factor (VEGF) antibody, is an\nantiangiogenic agent clinically used for various cancers. However, repeated use of\nthis agent leads to tumor-decreased vascularity and hypoxia with activation of an\nHIF-1 signaling pathway, which results in drug delivery deficiency and induction of\nmalignant behaviors in tumors. Here, we developed a novel strategy to treat tumors\nwith bevacizumab-induced vascular decrease and hypoxia using 64Cu-diacetyl-bis\n(N4-methylthiosemicarbazone) (64Cu-ATSM), a potential theranostic agent, which\npossesses high tissue permeability and can target over-reduced conditions under\nhypoxia in tumors, with a human colon carcinoma HT-29 tumor-bearing mouse model.\nThe long-term treatment with bevacizumab caused decreased blood vessel density\nand activation of an HIF-1 signaling pathway; increased uptake of 64Cu-ATSM was also\nobserved despite limited blood vessel density in HT-29 tumors. In vivo high-resolution\nSPECT/PET/CT imaging confirmed reduced vascularity and increased proportion of\n64Cu-ATSM uptake areas within the bevacizumab-treated tumors. 64Cu-ATSM therapy\nwas effective to inhibit tumor growth and prolong survival of the bevacizumab-treated\ntumor-bearing mice without major adverse effects. In conclusion, 64Cu-ATSM therapy\neffectively enhanced anti-tumor effects in tumors with bevacizumab-induced vascular\ndecrease and hypoxia. 64Cu-ATSM therapy could represent a novel approach as an add-on to antiangiogenic therapy.","subitem_description_type":"Abstract"}]},"item_8_publisher_8":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"Inpact Journals"}]},"item_8_relation_13":{"attribute_name":"PubMed番号","attribute_value_mlt":[{"subitem_relation_type_id":{"subitem_relation_type_id_text":"29179478","subitem_relation_type_select":"PMID"}}]},"item_8_relation_14":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_type_id":{"subitem_relation_type_id_text":"10.18632/oncotarget.21323","subitem_relation_type_select":"DOI"}}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"metadata only access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_14cb"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Yoshii, Yukie"}],"nameIdentifiers":[{"nameIdentifier":"486662","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Yoshimoto, Mitsuyoshi"}],"nameIdentifiers":[{"nameIdentifier":"486663","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Matsumoto, Hiroki"}],"nameIdentifiers":[{"nameIdentifier":"486664","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Furukawa, Takako"}],"nameIdentifiers":[{"nameIdentifier":"486665","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Zhang, Ming-Rong"}],"nameIdentifiers":[{"nameIdentifier":"486666","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Inubushi, Masayuki"}],"nameIdentifiers":[{"nameIdentifier":"486667","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Tsuji, Atsushi"}],"nameIdentifiers":[{"nameIdentifier":"486668","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Fujibayashi, Yasuhisa"}],"nameIdentifiers":[{"nameIdentifier":"486669","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Higashi, Tatsuya"}],"nameIdentifiers":[{"nameIdentifier":"486670","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Saga, Tsuneo"}],"nameIdentifiers":[{"nameIdentifier":"486671","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"吉井 幸恵","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"486672","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"張 明栄","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"486673","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"辻 厚至","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"486674","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"東 達也","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"486675","nameIdentifierScheme":"WEKO"}]}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"64Cu-ATSM internal radiotherapy to treat tumors with bevacizumab-induced vascular decrease and hypoxia in human  colon carcinoma xenografts     ","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"64Cu-ATSM internal radiotherapy to treat tumors with bevacizumab-induced vascular decrease and hypoxia in human  colon carcinoma xenografts     "}]},"item_type_id":"8","owner":"1","path":["1"],"pubdate":{"attribute_name":"公開日","attribute_value":"2017-12-07"},"publish_date":"2017-12-07","publish_status":"0","recid":"48414","relation_version_is_last":true,"title":["64Cu-ATSM internal radiotherapy to treat tumors with bevacizumab-induced vascular decrease and hypoxia in human  colon carcinoma xenografts     "],"weko_creator_id":"1","weko_shared_id":-1},"updated":"2023-05-15T23:28:22.611599+00:00"}